Feature|Videos|June 3, 2026

An End-to-End Approach to Specialty Patient Services

Key Takeaways

  • Learn how Inizio Engage's hub model integrates a non-dispensing pharmacy, automation, and clinical navigators to reduce friction across the patient access journey.
  • Explain how field reimbursement teams use real-time data and targeting strategies to support providers and improve patient therapy initiation in rare disease settings.
SHOW MORE

Streamlined hub services, clinical navigators, and data-driven field reimbursement are transforming the rare disease patient journey.

Sponsored by Inizio Engage

Jason Rains, Senior Vice President, Patient Access, and Randy Quist, Vice President, Field Reimbursement, at Inizio Engage presented the company’s end-to-end patient support model built on 25 years of nurse clinical education experience. The approach centers on a non-dispensing pharmacy that streamlines the front end of the treatment process, while smart automation moves patients through benefits investigation and prior authorization in the middle. Clinical nurse navigators serve as a single point of contact for patients, while field reimbursement managers handle provider-facing coordination, with both roles supported by the company's proprietary Trak360 platform built on Salesforce. With a four-quadrant analytics framework—descriptive, diagnostic, prescriptive, and predictive—reliable reporting data is able to inform actionable program insights. These changes unite data with human engagement to provide the best therapy for rare disease patients today.


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.